Integrated DNA Technologies Reagents

The Colorado Department of Public Health and Environment (CDPHE), Division of Communicable Disease and Prevention (DCPHR), Lab Services section is procuring Integrated DNA Technologies (IDT) reagents through a sole source contract modification for Denver County and Denver City jurisdictions. The procurement encompasses custom and pre-designed oligonucleotides, including primers, probes, panels, and kits necessary for viral testing workflows used in the Wastewater (WW) and Sequencing (SEQ) Genomic Surveillance Program units for research, surveillance, and diagnostic purposes. The contract term extends from August 1, 2024, through August 1, 2029, representing a five-year agreement. IDT has been designated as the sole source provider due to its proprietary rights to specific probe designs and synthesis technologies, CDC designation as a sole source for primers, probes, and panels, and current integration into all existing WW and Seq workflows. The procurement was posted on April 9, 2026, with a due date of April 14, 2026. No evaluation criteria are referenced in the justification, as this is a sole source procurement rather than a competitive bidding process. The original contract was estimated at $650,000; however, this modification increases the total contract value to $1,700,000 (an increase of $1,050,000) based on identified needs for a surge panel estimated at $180,000 and increased testing capacity requirements.

As a sole source procurement, this opportunity does not accept competitive responses from other vendors or organizations. The revised dollar amount of $1,700,000 was calculated using FY 2025/2026 actual expenditures of $216,564.91 multiplied by three years of the remaining contract term, plus a 60 percent buffer for price increases, outbreak responses, and contingencies. Historical price comparisons demonstrate fair and reasonable pricing relative to market alternatives, including Illumina offerings that are actually manufactured by IDT and repackaged. IDT is the incumbent vendor and current contractor, with established integration into existing WW and Seq workflows that precludes integration of alternative providers' technology. No conflicts of interest were identified in the procurement, and the contract modification was approved by Shannon Matzinger, Program Manager, and Alexandria Rossheim on March 27, 2026. This sole source justification reflects the technical necessity and operational dependency on IDT's proprietary technologies for the state's genomic surveillance program.